Antidepressant potential of nitrogen-containing heterocyclic moieties: An updated review

Journal of Pharmacy and Bioallied Sciences

Volumn 3, Issue 2, 2011, Pages 194-212

  Siddiqui, Nadeem ^a   Andalip, ^a   Bawa, Sandhya ^a   Ali, Ruhi ^a   Afzal, Obaid ^a   Akhtar, M ^a   Azad, Bishmillah ^a   Kumar, Rajiv ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Antidepressant; depression; heterocyclic

Indexed keywords

1 (4 INDOLYL)PIPERAZINE; 2 (1H INDOL 4 YLOXY)ETHYLAMINE; 2 (5H [1,2,4]TRIAZINO[5,6 B]INDOL 3 YLTHIO) N (SUBSTITUTED PHENYL)ACETAMIDE DERIVATIVE; 2 [3 (5 FLUORO 1H INDOL 3 YL) PROPYL] 6 METHOXY 1,2,3,4 TETRAHYDRO ISOQUINOLINE; 4 (3,4 DICHLOROPHENYL) 4 (1H INDOL 4 YL) N METHYLBUTAN 1 AMINE; 4 (5 FLUORO 1H INDOL 3 YL)CYCLOHEXYLAMINE; 4 [3 (1,2,3,6 TETRAHYDROPYRIDIN 4 YL) 1H INDOLE 1 SULFONYL]PHENYLAMINE; 4 AMINO ETHYL 3 (PHENYL SULFONYL) 1 H INDOLE; 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; 5,6 DIBROMO N,N DIMETHYLTRYPTAMINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ANTIDEPRESSANT AGENT; ARYLPIPERAZINE 4 YL CYCLOHEXYLINDOLE; ARYLSULFONYL 3 (1,2,3,6 TETRAHYDROPYRIDIN 4 YL)INDOLE DERIVATIVE; FLUOXETINE; HETEROCYCLIC COMPOUND; IMIDAZOLE DERIVATIVE; IMIPRAMINE; INDOLE DERIVATIVE; MITRAGYNINE; MOCLOBEMIDE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; QUINOLINE DERIVATIVE; SB243213; THIADIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DEPRESSION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 79957574223     PISSN: None     EISSN: 09757406     Source Type: Journal    
DOI: 10.4103/0975-7406.80765     Document Type: Review

References (120)

1. Srinath R, Pinkal DV, Saravanan J, Pravin SJ, Prashant R, Aravind S. Synthesis and evaluation of Antidepressant like Activity of Some Novel Thieno-1,2,3-triazine 4-ones. Int J Res Pharm Sci 2010;1:143-50.
2. Lucas MC, Weikert RJ, Carter DS, Cai HY, Greenhouse R, Lyer PS, et al. Design, synthesis and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain. Bioorg Med Chem Lett 2010;20:5559-66.
3. Iversen L, Glennon RA. Antidepressants. In: Abraham DJ. Burger's Medicinal Chemistry and Drug Discovery. 6th ed, vol. 6. New York: John wiley and sons publication; 1998. p. 483-524.
4. Gilman A, Goodman L. Drug therapy of depression and anxiety disorders. In: Brunton L, Parker K, Blumenthal D, Buxton I. Goodman and Gilman's Manual of Pharmacology and Therapeutics.7th ed. New York: McGraw-Hill; 2008. p. 278-98.
5. Wenga Z, Li J. Synthesis and antidepressant activity of optical isomers of 2-(4-benzylpiperazin-1-yl)-1-(5-chloro-6-methoxynaphthalen-2-yl) propan-1-ol (SIPI5056). Bioorg Med Chem Lett 2010;20:1256-9.
6. Fishback JA, Robson MJ, Xu YT, Matsumoto RR. Sigma receptors: Potential targets for a new class of antidepressant drug. Pharmacol Ther 2010;127:271-82.
7. Aboukhatwa MA, Undieh AS. Antidepressant stimulation of CDP-diacylglycerol synthesis does not require monoamine reuptake inhibition. BMC Neurosci 2010;11:10.
8. Sanchez C. Allosteric modulation of monoamine transporters-new drug targets in depression. Drug Discov Today Ther Strateg 2006;3:483-8. (Pubitemid 46076173)
9. Ben-Daniel R, Deuther-Conrad W, Scheunemann M, Steinbach J, Brust P, Mishani E. Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter. Bioorg Med Chem 2008;16:6364-70. (Pubitemid 351783418)
10. Mattson RJ, Catt JD, Denhart DJ, Deskus JA, Ditta JL, Higgins MA, et al. Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors. J Med Chem 2005;48:6023-34.
11. Biradar JS, Sasidhar BS, Parveen R. Synthesis, antioxidant and DNA cleavage activities of novel indole derivatives. Eur J Med Chem 2010;45:4074-8.
12. Csomós P, Fodor L, Bernáth G, Csámpai A, Sohár P. Synthesis of 4-thiaharmalan analogue 4-aryl-1,3-thiazino[5,6-b] indole derivatives by prevention of rearrangements to position two of the indole moiety. Tetrahedron. 2008;64:8646-51.
13. Farah Idayua N, Taufik Hidayata M, Moklasa MA, Sharida F, Nurul Raudzaha AR, Shamima AR, et al. Antidepressant-like effect of mitragynine isolated from Mitragyna speciosa Korth in mice model of depression. Phytomedicine 2010 [In press].
14. 2C receptor inverse agonists with potential as antidepressant/anxiolytic agents. Bioorg Med Chem Lett 2000;10:1863-6.
15. Shelke SM, Bhosale SH. Synthesis, antidepressant evaluation and QSAR studies of novel 2-(5H-[1,2,4] triazino [5,6-b] indol-3- ylthio)-N-(substituted phenyl)acetamides. Bioorg Med Chem Lett 2010;20:4661-4.
16. 2A receptor antagonistsn: Identifation, synthesis and activity of novel 4-aminoethyl-3- (phenylsulfonyl)-1H-indoles. Bioorg Med Chem 2009;17:7802-15.
17. Manning JR, Sexton T, Childers SR, Davies HM. 1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors. Bioorg Med Chem Lett 2009;19:58-61.
18. Kochanowska AJ, Rao KV, Childress S, El-Alfy A, Matsumoto RR, Kelly M, et al. Secondary metabolites from three florida sponges with antidepressant activity. J Nat Prod 2008;71:186-9. (Pubitemid 351362975)
19. 1A receptor and serotonine transporter affinity within a class of arylpiperazinyl-cyclohexyl indole derivateves. Bioorg Med Chem 2008;16:6707-23.
20. 6 ligands. Bioorg Med Chem Lett 2008;18:3929-31.
21. Deskus JA, Epperson JR, Sloan CP, Cipollina JA, Dextraze P, Qian-Cutrone J, et al. Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors. Bioorg Med Chem Lett 2007;17:3099-104.
22. Mahaney PE, Vu AT, McComas CC, Zhang P, Nogle LM, Watts WL, et al. Synthesis and activity of a new class of dual acting norepinephrine and serotonine reuptake inhihibitor: (3-(1H-indole-1-yl)-3-arylpropan- 1-amines. Bioorg Med Chem 2006;14:8455-66.
23. Evrard DA, Zhou P, Yi SY, Zhou D, Smith DL, Sullivan KM, et al. Studies towards the next generation of antidepressants. Part 4: Derivatives of 4-(5-fluoro-1H-indol-3-yl)cyclohexylamine with affinity for the serotonin transporter and the 5-HT1A receptor. Bioorg Med Chem Lett 2005;15:911-4. (Pubitemid 40458622)
24. 6 receptor antagonists. Bioorg Med Chem Lett 2005;15:379-83.
25. Schmitz WD, Denhart DJ, Brenner AB, Ditta JL, Mattson RJ, Mattson GK, et al. Homotryptamines as potent and selective serotonin reuptake inhibitors (SSRIs). Bioorg Med Chem Lett 2005;15:1619-21. (Pubitemid 40312541)
26. Kolanos R, Siripurapu U, Pullagurla M, Riaz M, Setola V, Roth BL, et al. Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett 2005;15:1987-98.
27. Heinrich T, Böttcher H. A new synthesis of indole 5- carboxylic acids and 6- hydroxyl- indole-5-carboxylic acids in the preparation of an o-hydroxyated of vilazodone. Bioorg Med Chem Lett 2004;14:2681-4. (Pubitemid 38519073)
28. 1A antagonist component into a class of serotonin reuptake inhibitors. Bioorg Med Chem Lett 2002;12:307-10.
29. Meagher KL, Mewshaw RE, Evrard DA, Zhou P, Smith DL, Scerni R, et al. Studies towards the next generation of antidepressants. Part 1: Indolylcyclohexylamines as potent serotonin reuptake inhibitors. Bioorg Med Chem Lett 2001;11:1885-988.
30. 1B/1D antagonistic activity: A new approach toward efficient antidepressants. J Med Chem 2000;43:1149-57.
31. Primofiore G, Marini AM, Settimo FD, Franzone JS, Mason U, Reboani MC, et al. N-(Indole-3-ylglyoxylyl) dopamine derivatives: Preparation and antidepressant activity. Eur J Med Chem 1998;23:397-401.
32. Ergenc N, Gunay NS, Demirdamar R. Synthesis and antidepressant evaluation of new 3- phenyl-5-sulfonamidoindole derivatives. Eur J Med Chem. 1998;33:143-8. (Pubitemid 28152316)
33. Sah P, Bidawat P, Seth M, Gharu CP. Synthesis of formazans from Mannich base of 5-(4-chlorophenyl amino)-2-mercapto-1,3,4- thiadiazole as antimicrobial agents. Arabian J Chem 2010 [In press].
34. Castro A, Castaño T, Encinas A, Porcaland W, Gil C. Advances in the synthesis and recent therapeutic applications of 1,2,4-thiadiazole heterocycles. Bioorg Med Chem 2006;14:1644-52.
35. Clerici F, Pocar D, Guido M, Loche A, Perlini V, Brufani M. Synthesis of 2-amino-5-sulfanyl-1,3,4-thiadiazole derivatives and evaluation of their antidepressant and anxiolytic activity. J Med Chem 2001;15:931-6.
36. Clerici F, Pocar D, Guido M, Loche A, Perlini V, Brufani M. Synthesis of 2-Amino-5-sulfanyl-1,3,4-thiadiazole derivatives and evaluation of their antidepressant and anxiolytic activity. J Med Chem 2001;44:931-6.
37. Yusuf M, Khan RA, Ahmed B. Syntheses and anti-depressant activity of 5-amino-1,3,4- thiadiazole-2-thiol imines and thiobenzyl derivatives. Bioorg Med Chem 2008;16:8029-34.
38. Pattanayak P, Sharma R, Sahoo PK. Synthesis and evaluation of 2-amino-5-sulfanyl-1,3,4-thiadiazole as antidepressant, anxiolytic, and anticonvulsant agents. Med Chem Res 2009;18:351-61.
39. Sharma R, Mishra GP, Sainey J, Chaturvedi SC. Synthesis and biological evaluation of 2-amino-5-sulfanyl-1,3,4-thiadiazole derivatives as antidepressant, anxiolytics and anticonvulsants agents. Med Chem Res 2010 [In press].
40. Varvaresou A, Siatra-Papastaikoudi T, Dalla Tsotinis A, Tsantili-Kakoulidou A, Vamvakides A. Synthesis, lipophilicity and biological evaluation of indole-containing derivatives of 1,3,4- thiadiazole and 1,2,4-triazole. Farmaco 1998;53:320-6.
41. Jatav V, Mishra P, Kashaw S, Stables JP. CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl] -2-styryl quinazoline-4(3H)-ones. Eur J Med Chem 2008;43:1945-54.
42. 1A receptor antagonism/SSRI activities. Part 1. Bioorg Med Chem Lett 2003;13:1903-5.
43. Källström S, Leino R. Synthesis of pharmaceutically active compounds containing a disubstituted piperidine framework. Bioorg Med Chem 2008;16:601-35. (Pubitemid 351163050)
44. Layer RT, Popik P, Olds T, Skolnick P. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol Biochem Behav 1995;52:621-7.
45. 1A receptor antagonism/SSRI activities. Part 5. Bioorg Med Chem Lett 2006;16:2347-51.
46. 1A superagonists. J Med Chem 2010;53:7167-79.
47. Boot JR, Boulet SL, Clark BP, Cases-Thomas MJ, Delhaye L, Diker K, et al. N-alkyl-N-arylmethylpiperidin-4-amines: Novel dual inhihibitors of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett 2006;16:2714-8.
48. 1A receptor antagonism/SSRI activities. Part 4. Bioorg Med Chem Lett 2004;14:2653-6.
49. Steckler TH, Janssens FE, Leenaerts JE, Fernandez-Gadea FJ, Gomez-Sanchez A, Meert TF. Substituted 4-phenyl-4-(1H-Imidazole-2- yl)-Piperidine derivatives as selective non-peptide delta opiod agonist with antidepressant and anxiolytic activity. US Patents. 2006;31:513.
50. Trabanco AA, Aerts N, Alvarez RM, Andrés JI, Boeckx I, Fernández J, et al. 4-phenyl-4-(1H-imidazol-2-yl)-piperidine derivatives as non-peptides selective opiod agonist with potential anxiolytic/ antidepressant properties. Part2. Bioorg Med Chem Lett 2007;17:3860-3.
51. Ahmad YE, Maillet P, Laurent E, Talab A, Teste JF, Cedat MJ, et al. New N-(benzhydroxyalkyl)-4-(carboxy/carbamoylmethyl) piperidine derivatives with antidepressant activity. Eur J Med Chem 1997;32:205-18. (Pubitemid 27154291)
52. 1A receptor antagonism/SSRI Activities. Part 3. Bioorg Med Chem Lett 2003;13:3939-42.
53. 1A receptor antagonism/SSRI activities. Part 2. Bioorg Med Chem Lett 2003;13:2393-7.
54. Ong HH, Profitt JA, Fortunato J, Glamkowski EJ, Ellis DB, Geyer HM, et al. Novel tetracyclic spiropiperidines. 3. 1-Arylspiro[indoline-3,4′- piperidine]s as potential antidepressants. J Med Chem 1983;26:981-6.
55. Wang J, Mack AL, Coop A, Matsumoto RR. Novel sigma (σ) receptor agonists produce Antidepressant like effects in mice. Eur Neuropsychopharmacol 2007;17:708-16. (Pubitemid 47419291)
56. Balsamo A, Giorgi I, Lapucci A, Lucacchini A, Macchia B, Macchia F, et al. 3-[(2-Ethoxyphenoxy)methyl]piperidine derivatives. Synthesis and antidepressant activity. J Med Chem 1987;30:222-5.
57. He R, Kurome T, Giberson KM, Johnson KM, Kozikowski AP. Further structure-activity relationship studies of piperidine-based monoamine transporter inhibitors: Effects of piperidine ring stereochemistry on potency. Identification of norepinephrine transporter selective ligands and broad-spectrum transporter inhibitors. J Med Chem 2005;48:7970-9. (Pubitemid 41798428)
58. Orjales A, Mosquera R, Toledo A, Pumar M, García N, Cortizo L, et al. Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters. J Med Chem 2003;46:5512-32. (Pubitemid 37490382)
59. Vacher B, Bonnaud B, Funes P, Jubault N, Koek W, Assie MB, et al. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors. J Med Chem 1999;42:1648-60. (Pubitemid 29226734)
60. 1A partial agonists. Bioorg Med Chem Lett 2009;19:6604-7.
61. 2C, and the serotonin transporter as a potential antidepressant. Bioorg Med Chem Lett 2010;20:6439-42.
62. 2C receptor stimulation; suggestive of antipsychotic potential. Pharmacol Biochem Behav 2011;97:479-85.
63. Raghavan N, Zhang D, Zhu M, Zeng J, Christopher L. CYP2D6 catalyzes 5-hydroxylation of 1-(2-pyrimidinyl)-piperazine, an active metabolite of several psychoactive drugs, in human liver microsomes. Drug Metab Dispos 2005;33:203-8. (Pubitemid 40227464)
64. Bishnoi A, Srivastava K, Singh S, Tripathi CM. Synthesis of some novel piperazine salts and their antimicrobial property against Escherichia coli and Bacillus subtilis. Der Pharma Chemica 2010;2:446-52.
65. 1A receptor agents with anxiolytic- like activity. Bioorg Med Chem 2006;14:1391-402.
66. Jonathan Fray M, Bish G, Brown AD, Fish PV, Stobie A, Wakenhut F, et al. N-(1,2-Diphenylethyl)piperazine: A new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett 2006;16:4345-8.
67. 2C, and the serotonin transporter as a potential antidepressant. Bioorg Med Chem Lett 2010;20:1705-11.
68. 1B antagonists as potential antidepressant drug. Bioorg Med Chem Lett 2005;15:5567-73.
69. 1D antagonist activity: Chemistry and pharmacological evaluation of a series of thienopyran derivatives. Bioorg Med Chem 2004;12:5277-99.
70. 2A receptor affinity, and in vivo pharmacological evaluation. Bioorg Med Chem 2007;15:2907-19.
71. 7 receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl) piperazines. Bioorg Med Chem 2007;15:7116-25.
72. 7 receptor antagonists. Bioorg Med Chem 2008;16:5405-12.
73. 1A/SSRI activities. Chin Chem Lett 2008;19:291-4.
74. Weng Z, Li J. Synthesis and antidepressant activity of optical isomers of 2-(4-benzylpiperazin-1-yl)-1-(5-chloro-6-methoxynaphthalen-2-yl) propan-1-ol(SIPI5056). Bioorg Med Chem Lett 2010;20:1256-9.
75. 2 activity as potential anxiolytic and antidepressant agents. J Med Chem 1999;42:5077-94.
76. 1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem 1997;40:3974-8.
77. Mahaney PE, Gavrin LK, Trybulski EJ, Stack GP, Vu AT, Cohn ST, et al. Structure-activity relationships of the cycloalkanol ethylamine scaffold: Discovery of selective norepinephrine reuptake inhibitors. J Med Chem 2008;51:4038-49. (Pubitemid 351956531)
78. Bermack JE, Haddjeri N, Debonnel G. Effects of the potential antidepressant OPC-14523 [1-[3-[4-(3-chlorophenyl)-1-piperazinyl] propyl]-5-methoxy-3,4-dihydro-2-quinolinone monomethanesulfonate] a combined σ and 5-HT1A ligand: Modulation of neuronal activity in the dorsal raphe nucleus. J Pharmacol Exp Ther 2004;310:578-83. (Pubitemid 38988902)
79. Naoi M, Nagatsu T. Quinoline and quninaldine as naturally occurring inhibitors specific for type A monoamine oxidase. Life Sci 1987;40:1075-82. (Pubitemid 17025626)
80. Kategaonkar AH, Shinde PV, Kategaonkar AH, Pasale SK, Shingate BB, Shingare MS. Synthesis and biological evaluation of new 2-chloro-3- ((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)quinoline derivatives via click chemistry approach. Eur J Med Chem 2010;45:3142-6.
81. Guentert TW, Daly JJ, Riegelman S. Isolation, characterisation and synthesis of a new quinidine metabolite. Eur J Drug Metab Pharmacokinet 1982;7:31-38. (Pubitemid 12187200)
82. Oshiro Y, Sakurai Y, Sato S, Kurahashi N, Tanaka T, Kikuchi T, et al. 3,4-Dihydro-2(1H)-quinolinone as a novel antidepressant drug: Synthesis and pharmacology of 1-[3-[4-(3-Chlorophenyl)-1-piperazinyl] propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives. J Med Chem 2000;43:177-89. (Pubitemid 30078149)
83. Beadle CD, Boot J, Camp NP, Dezutter N, Findlay J, Hayhurst LM, et al. 1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett 2005;15:4432-7. (Pubitemid 41253870)
84. Tran M, Stack GP. Antidepressant Azaheterocyclymethyl derivatives of 2, 3- dihydro-1,4- dioxino(2,3-F)quinoline. US Patent. 2002/0165245 A1.
85. 1B antagonists. Bioorg Med Chem 2007;15:939-50.
86. 1A/B/D receptor antagonists. J Med Chem 2008;51:2887-90.
87. Kumar S, Bawa S, Drabu S, Gupta H, Machwal L, Kumar R. Synthesis, antidepressant and antifungal evaluation of novel 2-chloro-8- methylquinoline amine derivatives. Eur J Med Chem 2011;46:670-5.
88. Barsoum FF, Girgis AS. Facile synthesis of bis(4,5-dihydro-1Hpyrazole- 1-carboxamides) and their thio-analogues of potential PGE2 inhibitory properties. Eur J Med Chem 2009;44:2172-7.
89. Siddiqui N, Alam P, Ahsan W. Design, synthesis, and in-vivo pharmacological screening of N,3-(substituted diphenyl)-5-phenyl- 1H-pyrazoline-1-carbothioamides derivatives. Arch Pharm (Weinheim) 2009;342:173-81.
90. Palaska E, Aytemir M, Uzbay IT, Erol D. Synthesis of antidepressant activities of some 3,5-diphenyl-2-pyrazolines. Eur J Med Chem 2001;36:539-43. (Pubitemid 32781717)
91. Ozdemir Z, Kandilci HB, Gümüşel B, Caliş U, Bilgin AA. Synthesis of studies on antidepressant and anticonvusant activities of some 3-(2-furyl)-pyrazoline derivatives. Eur J Med Chem 2007;42:373-9. (Pubitemid 46349364)
92. Can OZ, Ozkay UD, Kaplancikli ZA, Oztürk Y. Effect of some 1.3,4- trisubtituted-2-pyrazoline derivatives on depression and anxiety parameters of mice. Arch Pharm Res 2009;32:1293-9.
93. Gok S, Demet MM, Ozdemir A, Turan-Zitouni G. Evaluation of antidepressant- like effect of 2-pyrazoline derivatives. Med Chem Res 2010;19:94-101.
94. Abdel-Aziz M, Abuo-Rahma G, Hassan AA. Synthesis of novel pyrazole derivatives and evaluation of their antidepressantand anticonvulsant activities. Eur J Med Chem 2009;44:3480-7.
95. Cheng H, Hoffman J, Le P, Nair SK, Cripps S, Matthews J, et al. The development and SAR of pyrrolidine carboxamide 11β-HSD1 inhibitors. Bioorg Med Chem Lett 2010;20:2897-902.
96. 2A receptor affinity of spiro[9,10- dihydroanthracene]-9, 3′-pyrrolidine (SpAMDA). Bioorg Med Chem Lett 2004;14:2279-83.
97. Cheng XC, Wang Q, Fang H, Tang W, Xu WF. Synthesis of new sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors. Bioorg Med Chem 2008;16:7932-8.
98. Yoon T, De Lombaert S, Brodbeck R, Gulianello M, Chandrasekhar J, Horvath RF, et al. The design, synthesis and structure-activity relationships of 1-aryl-4-aminoalkyl isoquinolines: A novel series of CRF-1 receptor antagonists. Bioorg Med Chem Lett 2008;18:891-6. (Pubitemid 351179366)
99. DeMet EM, Vosmer G, Halaris AE. Noncompetitive amine uptake inhibition by the new antidepressant pridefine. J Neurochem 1981;36:917-23. (Pubitemid 11100077)
100. Hancock AA, Buckner SA, Giardina WJ, Brune ME, Lee JY, Morse PA, et al. Preclinical pharmacological actions of (+/-)-(1′R*,3R*)-3- phenyl-1- [1′,2′,3′,4′-tetrahydro-5′,6′- methylene-dioxy-1′-naphthalenyl) methyl] pyrrolidine methanesulfonate (ABT-200), a potential antidepressant agent that antagonizes alpha-2 adrenergic receptors and inhibits the neuronal uptake of norepinephrine. J Pharmacol Exp Ther 1995;272:1160-9.
101. Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre-y-Hernández M, et al. "Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives". Eur Arch Psychiatry Neurol Sci 1988;238:2-6. (Pubitemid 19008259)
102. Banwart LM, Carter DS, Cai HY, Choy JC, Greenhouse R, Jaime- Figueroa S, et al. Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett 2008;18:6062-6.
103. Zelle RE, Hancock AA, Buckner SA, Basha FZ, Tieje K, Debernardis JF, et al. Synthesis and pharmacological characterization of ABT-200:A putative novel antidepressant combining potent α-2 antagonism with moderate NE uptake inhibition. Bioorg Med Chem Lett 1994;4:1319-22. (Pubitemid 24205606)
104. Hadizadeh F, Hosseinzadeh H, Motamed-Shariaty VS, Seifi M, Kazemi S. Synthesis and antidepressant activity of N-substituted imidazole-5-caboxamide in forced swimming test model. Iran J Pharm Res 2008;7:29-33. (Pubitemid 351943806)
105. 1A receptor agonist with potential antidepressant and anxiolytic activity. Eur J Med Chem 2010;45:1295-303.
106. Zagorska A, Jurczy S, Pawlowski M, Dybala M, Nowak G, Tatarczynska E, et al. Synthesis and preliminary pharmacological evaluation of imidazo(2,1-f) purine-2,4-dione derivatives. Eur J Med Chem 2009;44:4288-96.
107. Ulak G, Mutlu O, Akar FY, Komsuoǧlu FI, Tanyeri P, Erden BF. Neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole augment the effects of antidepressants acting via serotonergic system in the forced swimming test in rats. Pharmacol Biochem Behav 2008;90:563-8.
108. Rodriguez F, Rozas I, Ortega JE, Erdozain AM, Meana JJ, Callado LF. Guanidine and 2-aminoimidazoline aromatic derivatives as α2-adrenoceptor antagonists. 2. Exploring alkyl linkers for new antidepressants. J Med Chem 2008;51:3304-12.
109. 1A activity. Part 3. Eur J Med Chem 2011;46:142-9.
110. Rodrigues ALS, Rosa JM, Gadotti VM, Goulart EC, Santos MM, Silva AV, et al. Antidepressant-like antinociceptive-like action of 4-(4′- cholorophenyl)-6-(4″-methylphenyl)-2-hydrazinepyrimidine Mannich base in mice. Pharmacol Biochem Behav 2005;82:156-62. (Pubitemid 41423499)
111. 1A activity. Part 1. Eur J Med Chem 2009;44:1710-7.
112. 1A activity: Part2. Eur J Med Chem 2009;44:4702-15.
113. Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, et al. Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant. Bioorg Med Chem Lett 2010;20:6439-42.
114. Gupta RR, Kumar M, Gupta V. Heterocyclic Chemistry: Five Membered Heterocycles. : Berlin, Heidelberg, New York: Springer-Verlag; 1999. p. 492-3.
115. Finar IL. Organic Chrmistry: Stereochemistry and the Chemistry of Natural Product. 5th ed, vol. 2. India: Pearson education 2004; p. 621-622.
116. Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990;26:311-5. (Pubitemid 20386901)
117. El Shehry MF, Abu-Hashem AA, El-Telbani EM. Synthesis of 3-((2,4-dichloro phenoxy)methyl)-1,2,4-triazolo(thiadiazoles and thiadiazines) as anti-inflammatory and molluscicidal agents. Eur J Med Chem 2010;45:1906-11.
118. Kapilncki ZA, Ozdemir A, Turan-Zitouni G, Altintop MD, Can OD. New Pyrazoline derivatives and their antidepressant activity. Eur J Med Chem 2010;45:4383-7.
119. Kane JM, Dudley MW, Sorensen SN, Miller FP. 2,4-Dihydro-3-H-1,2,4- triazole-3-thiones as potential antidepressant agents. J Med Chem 1988;31:1253-8.
120. Varvaresou A, Siatra-Papastaikoudi T, Dalla Tsotinis A, Tsantili- Kakoulidou A, Vamvakides A. Synthesis, lipophilicity and biological evaluation of indole-containing derivatives of 1,3,4-thiadiazole and 1,2,4-triazole. Farmaco 1998;53:320-6.